文献速递其他结缔组织病

原发性干燥综合征患者接受阿巴西普治疗48周的长期疗效:ASAP-III试验开放标签扩展期

Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
PubMed 文献 · Semin Arthritis Rheum · 2022-01-10

ASAP-III试验开放标签扩展期纳入40例原发性干燥综合征患者,从基线至第48周持续接受阿巴西普治疗。第48周中位ESSDAI从基线14.0降至4.0(p<0.001),50%患者达到低疾病活动度(ESSDAI<5);中位ESSPRI从7.0降至5.0(p<0.001);73%患者为CRESS应答者。

要点

  • 40例患者接受阿巴西普治疗48周,中位ESSDAI从14.0降至4.0(p<0.001)。
  • 第48周50%患者达到低疾病活动度(ESSDAI<5),73%为CRESS应答者。
  • 中位ESSPRI从7.0降至5.0(p<0.001),干眼和实验室检查亦有改善。

核心结论

  • 在ASAP-III试验开放标签扩展期中,阿巴西普治疗至48周时,临床、患者报告、干眼和实验室结局均见改善,大多数患者在第48周为CRESS应答者。

研究设计与样本

  • 单中心ASAP-III试验包括随机双盲安慰剂对照期(基线至第24周,1:1随机分组,结果已发表)和开放标签扩展期(第24周至48周,所有患者接受阿巴西普)。
  • 主要纳入标准为符合AECG标准、腺体活检阳性、病程≤7年且ESSDAI≥5。
  • 在从基线至第48周接受阿巴西普治疗的患者中评估临床、患者报告、腺体和实验室结局指标,并分析CRESS应答(5项中≥3项应答)。

主要发现

  • 接受阿巴西普治疗48周的患者(n=40)中位ESSDAI从基线14.0(IQR 9.0-16.8)改善至第48周4.0(2.0-8.0)(p<0.001)。
  • 第48周50%患者达到低疾病活动度(ESSDAI<5)。
  • 中位ESSPRI从7.0(IQR 5.4-7.7)改善至5.0(3.7-6.7)(p<0.001)。
  • 干眼和实验室检查亦见显著改善。
  • 第48周73%患者为CRESS应答者;第24周至第48周阿巴西普治疗期间可见进一步改善。

关键数值与推荐

  • 低疾病活动度定义为ESSDAI<5,第48周50%患者达到。
  • CRESS应答定义为5项中≥3项应答,第48周73%患者达到。
  • 主要纳入标准包括符合AECG标准、腺体活检阳性、病程≤7年且ESSDAI≥5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate treatment efficacy of long-term abatacept treatment in pSS patients. METHODS: The single-centre ASAP-III trial consisted of two phases: the randomised, double-blind, placebo-controlled phase (1:1 randomisation) from baseline to week 24, of which results have been published previously, and the open-label extension phase from week 24 to 48, in which all patients received abatacept. Main inclusion criteria were fulfilment of the AECG criteria, positive gland biopsy, disease duration ≤ 7 years and ESSDAI ≥ 5. Long-term treatment effects of abatacept on clinical, patient-reported, glandular and laboratory outcome measures were assessed in patients treated with abatacept from baseline to week 48. Furthermore, Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) response (response on ≥3 of 5 items) was analysed. RESULTS: In patients on abatacept treatment for 48 weeks (n = 40), median ESSDAI improved from baseline 14.0 (IQR 9.0-16.8) to 4.0 (2.0-8.0) at week 48 (p < 0.001), with 50% of patients reaching low disease activity (ESSDAI < 5) at week 48. Median ESSPRI improved from 7.0 (IQR 5.4-7.7) to 5.0 (3.7-6.7) (p < 0.001). Significant improvement was also seen in dry eye and laboratory tests. Combining response at multiple clinically relevant items, 73% of patients were CRESS responders at week 48. Additional improvement was seen between week 24 and week 48 of abatacept treatment. CONCLUSION: In the open-label extension phase of the ASAP-III trial, improvement was seen up to 48 weeks of abatacept treatment in clinical, patient-reported, dry eye and laboratory outcomes. The majority of patients were CRESS responders at week 48.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. de Wolff L, van Nimwegen JF, Mossel E, et al. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial. Semin Arthritis Rheum. 2022. PMID: 35091325. doi:10.1016/j.semarthrit.2022.151955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。